Do you have atopic dermatitis?

The TEZEPELUMAB study: A clinical trial to assess a new drug for atopic dermatitis

he purpose of the study is to evaluate the safety and effectiveness of the study drug tezepelumab alone, or in combination with a topical corticosteroid, in the treatment of moderate to severe atopic dermatitis. Atopic dermatitis is a chronic, inflammatory skin condition with symptoms including areas of dry, itching and reddened skin. This study will also assess the safety and effectiveness of different doses of tezepelumab.

Tezepelumab is an experimental treatment which means that it is not an approved treatment for moderate to severe atopic dermatitis in Australia. Medications, drugs and devices have to be approved for use by the Therapeutic Goods Administration in Australia.

Anticipated date that encolment will close: TBA

Who can take part

Inclusion criteria

  • Age from 18 up to 75 years
  • At least 2 years of chronic atopic dermatitis
  • Inadequate response to topical corticosteroids

Exclusion criteria

  • Recent history of clinically significant infection
  • History of parasitic infection within last 6 months
  • History of anaphylaxis following any biologic therapy
  • Diagnosis of tuberculosis within last 12 months
  • History of hepatitis B or C
  • History of malignancy, except:
    • basal cell carcinoma and cervix carcinoma in situ carcinoma
    • other malignancies treated over 5 years ago
  • History or severe psychiatric illness

What is involved for you

  • 2 weekly visits for 64 weeks
  • blood/urine samples
  • chest x-ray
  • weight
  • blood pressure
  • injections
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2018.329
Annette Phemister
03 9342 4531